Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Buprenorphine Implants for Treatment of Opioid Dependence

Buprenorphine Implants for Treatment of Opioid Dependence ORIGINAL CONTRIBUTION Buprenorphine Implants for Treatment of Opioid Dependence A Randomized Controlled Trial Walter Ling, MD Context Limitations of existing pharmacological treatments for opioid dependence in- Paul Casadonte, MD clude low adherence, medication diversion, and emergence of withdrawal symptoms. George Bigelow, PhD Objective To determine the efficacy of buprenorphine implants that provide a low, steady level of buprenorphine over 6 months for the treatment of opioid dependence. Kyle M. Kampman, MD Design, Setting, and Participants A randomized, placebo-controlled, 6-month Ashwin Patkar, MD trial conducted at 18 sites in the United States between April 2007 and June 2008. Genie L. Bailey, MD One hundred sixty-three adults, aged 18 to 65 years, diagnosed with opioid depen- dence. One hundred eight were randomized to receive buprenorphine implants and Richard N. Rosenthal, MD 55 to receive placebo implants. Katherine L. Beebe, PhD Intervention After induction with sublingual buprenorphine-naloxone tablets, pa- EPENDENCE ON OPIOIDS, IN THE tients received either 4 buprenorphine implants (80 mg per implant) or 4 placebo im- form of heroin or prescrip- plants. A fifth implant was available if a threshold for rescue use of sublingual bu- prenorphine-naloxone treatment was exceeded. Standardized individual drug counseling tion pain medications, is a sig- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Loading next page...
 
/lp/american-medical-association/buprenorphine-implants-for-treatment-of-opioid-dependence-zm5gkeMs1k

References (30)

Publisher
American Medical Association
Copyright
Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2010.1427
pmid
20940383
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL CONTRIBUTION Buprenorphine Implants for Treatment of Opioid Dependence A Randomized Controlled Trial Walter Ling, MD Context Limitations of existing pharmacological treatments for opioid dependence in- Paul Casadonte, MD clude low adherence, medication diversion, and emergence of withdrawal symptoms. George Bigelow, PhD Objective To determine the efficacy of buprenorphine implants that provide a low, steady level of buprenorphine over 6 months for the treatment of opioid dependence. Kyle M. Kampman, MD Design, Setting, and Participants A randomized, placebo-controlled, 6-month Ashwin Patkar, MD trial conducted at 18 sites in the United States between April 2007 and June 2008. Genie L. Bailey, MD One hundred sixty-three adults, aged 18 to 65 years, diagnosed with opioid depen- dence. One hundred eight were randomized to receive buprenorphine implants and Richard N. Rosenthal, MD 55 to receive placebo implants. Katherine L. Beebe, PhD Intervention After induction with sublingual buprenorphine-naloxone tablets, pa- EPENDENCE ON OPIOIDS, IN THE tients received either 4 buprenorphine implants (80 mg per implant) or 4 placebo im- form of heroin or prescrip- plants. A fifth implant was available if a threshold for rescue use of sublingual bu- prenorphine-naloxone treatment was exceeded. Standardized individual drug counseling tion pain medications, is a sig-

Journal

JAMAAmerican Medical Association

Published: Oct 13, 2010

There are no references for this article.